Market revenue in 2021 | USD 214.2 million |
Market revenue in 2028 | USD 495.9 million |
Growth rate | 12.7% (CAGR from 2021 to 2028) |
Largest segment | Al |
Fastest growing segment | ATTR |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | AL, AA, ATTR |
Key market players worldwide | Pfizer Inc, Ionis Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Johnson & Johnson, Alnylam Pharmaceuticals Inc |
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to amyloidosis treatment market will help companies and investors design strategic landscapes.
Al was the largest segment with a revenue share of 46.17% in 2021. Horizon Databook has segmented the Middle East & Africa amyloidosis treatment market based on al, aa, attr covering the revenue growth of each sub-segment from 2018 to 2028.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa amyloidosis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa amyloidosis treatment market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account